Chinese COVID-19 immunization competitor shows guarantee in human preliminary: Study Kumar Jeetendra | October 16, 2020 One of China’s leading COVID-19 vaccine candidates, called BBIBP-CorV, was proven to be safe and elicited immune response in a small early-phase human trial, researchers said on Friday. A previous clinical trial reported similar results for a different vaccine that’s also based on inactivated whole SARS-CoV-2 virus, but in that study the vaccine was only …
Oxford University says COVID-19 patients experience symptoms months subsequent to contracting virus Kumar Jeetendra | October 19, 2020 Britain’s Oxford University said on Monday first findings from a study on the long term effect of COVID-19 has discovered a lot of patients discharged from hospitals still experience symptoms of breathlessness, fatigue, depression and anxiety two to three months after contracting the virus. The scientists detected abnormalities in many organs and believe persistent inflammation …
China’s Sinovac is sheltered, says Brazil’s leading research organization Kumar Jeetendra | October 20, 2020 São Paulo’s Butantan Institute, one of Brazil’s leading biomedical research centers, which is carrying out the Stage 3 tests, said the two-dose vaccine, called CoronaVac, was secure in a trial thus far involving 9,000 volunteers. But Butantan manager Dimas Covas said data on how effective the vaccine is will not be published until the trial …
USFDA supports remdesivir, first medication to treat Covid-19 patients Kumar Jeetendra | October 23, 2020 Washington: The United States Food and Drug Administration (FDA) has approved Remdesivir for the treatment of coronavirus, Al Jazeera reported citing a statement issued by Gilead Sciences, Inc.. Based on the press release by the company, previously authorised by the FDA for just emergency use to deal with Covid-19 patients, Veklury or Remdesivir is now …
GSK, Sanofi to make 200 million doses accessible for COVID-19 antibody union Kumar Jeetendra | October 28, 2020 French drugmaker Sanofi SA and Britain’s GlaxoSmithKline plan to create 200 million doses of the COVID-19 vaccine candidate accessible to the vaccine allocation program co-led by GAVI and the World Health Organization. The companies said on October 28 they have signed a statement of intent with vaccine alliance GAVI, which is coordinating the global plan …
Singapore working on making sure about arrangement of COVID-19 vaccines Kumar Jeetendra | November 10, 2020 Singapore will work towards procuring a”portfolio” of all COVID-19 vaccines to appeal to various parts of the populace instead of relying upon a single vaccine,” Health Minister Gan Kim Yong said on November 10. Speaking during a digital media conference by the multi-ministry job force on COVID-19, Gan said that the application of a vaccine …
Sinovac Biotech has secured $515 million in financing from a local company to double manufacturing capacity of its corona vaccine Kumar Jeetendra | December 7, 2020 China’s Sinovac Biotech has secured $515 million in financing from a local company to double manufacturing capacity of its coronavirus vaccine, the companies said on Monday, as it anticipates efficacy data of its experimental shot this month. The investment deal also comes as Sinovac expands provide deals and trials of its experimental COVID-19 vaccine CoronaVac …
Moderna COVID-19 shots leave distribution centers, broadening US vaccination push Kumar Jeetendra | December 20, 2020 Shipments of Moderna Inc’s COVID-19 vaccine started leaving warehouses early on Sunday, heading for healthcare facilities around the USA in a push to disperse the second authorized coronavirus vaccine. The distribution of Moderna’s vaccine to over 3,700 locations in the United States will vastly expand the rollout started a week by Pfizer Inc.. The U.S. …
Oxford COVID-19 vaccine may also come to be the primary to get Indian regulator’s nod for emergency use Kumar Jeetendra | December 26, 2020 With preparations underway for a possible vaccine-rollout by January, the Indian drug regulator is considering the united kingdom, which sources consider may give its nod to the Oxford COVID-19 vaccine following week, before deciding on giving emergency use authorisation to the Serum Institute that’s manufacturing the shots . When the UK drug regulator gives its …
Emergency use SEC approval for Bharat Biotech Covaxin Kumar Jeetendra | January 2, 2021 The SEC has recommended Covaxin for emergency use authorisation (EUA), reported news agency ANI quoting government sources. The recommendation, together with rollout modalities, will be taken up from the Drug Controller General of India (DCGI) to get a final decision on the issue. The Subject Expert Committee (SEC) of Central Drugs Standard Control Organisation (CDSCO) …
Russia prepared to trial combined AstraZeneca, Sputnik V antibody in Ukraine Kumar Jeetendra | January 3, 2021 Russia is ready to run clinical trials in Ukraine of a COVID-19 vaccine combining its Sputnik V with a vaccine developed by AstraZeneca together with Oxford University, the head of Russian Direct Investment Fund (RDIF) said on Saturday. Russia’s autonomous RDIF, which is marketing the Sputnik V vaccine overseas, announced in December trials to test …
Panthera began dosing volunteers in AstraZeneca’s phase III of its long-acting antibody combination AZD7442 for the prevention of COVID-19 at its sites in Preston, North Manchester and North London Kumar Jeetendra | January 5, 2021 Panthera’s clinical trial sites in Preston, North Manchester and North London began dosing volunteers in the Phase III PROVENT trial which will evaluate AstraZeneca’s long-acting antibody combination, AZD7442, for the potential prevention of COVID-19. The double-blind, placebo-controlled trial will include adult volunteers who have no history of COVID-19 and have an increased risk of infection, …
